Interestingly, T-ALL cells from the VADA-treated BMAT-poor sites also exhibited higher E-selectin-binding levels (median: 4.5% E-selectin+ cells) compared with untreated mice (Fig. 5C). The gene discussed is SELE; the disease is acute lymphoblastic leukemia.